Local Drug Delivery for the treatment of Periodontal Diseases

Phase 4

Completed

• Conditions: Administration,

• Registration Number: CTRI/2019/04/018697
• Lead Sponsor: not applicable

Brief Summary

Periodontitis,a chronic inflammatory disease, is induced by bacterial biofilms that initiatehost response in gingival connective tissue. It is considered an infection because there is abacterial etiology and an immune response. Sub gingivalenvironment is Ideal for pathogenic bacteria andSub gingival microorganisms are the principleetiologic factor in the development of periodontitis. Conventionaltherapy (e.g., scaling and root planing [SRP] and ultrasonic debridement)without adjunctive chemotherapy is often sufficient to suppress bacterialpathogens, thereby attaining periodontal health. Local delivery of antimicrobial agents in Periodonticsimplies antimicrobial therapy placed directly in the sub gingival region. Borinic acid are quinoline esters, arecently-identified class of new antibacterial compounds that contains boron. Itplays a role in inflammatory and immune response regulation. Italso plays a vital role in osteogenesis and the maintenance of bones.  Curcumin, the primary active constituent of turmeric exhibits anti-inflammatory, anti-oxidant, anticarcinogenic, antiviral, and antimicrobial activities. Therefore, the present study will be undertaken to evaluate and compare the effectiveness of boric acid gel and curcumin gel  as an adjunct to scaling and root planing in patients with chronic periodontitis.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-04-23
• Last Update Posted: 2020-01-02

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

• Patients motivated to have the therapy and willing to complete the follow-up.
• Patients with a minimum of 20 teeth.
• Subjects who readily give informed consent for the study.
• Systemically healthy subjects, with deep pockets.
• Patients with no history of periodontal therapy ij the preceding 6 months or under any antibiotic therapy.

Exclusion Criteria

• Patients on systemic boron therapy, those with a known or suspected allergy to boron supplementation or curcumin.
• Patients who have undergone periodontal therapy in the last 6 months.
• Patients who were taking and had consumed vitamin supplements, anti-inflammatory agents, or statins in the previous 3 months.
• Patients with any systemic disorder affecting periodontal health.
• Patients with infectious conditions other than periodontitis.
• Regular users of mouthwashes.
• Chronic alcoholics 8.
• Those with aggressive periodontitis.
• Immunocompromised and systemically unhealthy patients.
• Pregnant or lactating females.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Probing pocket depth reduction	baseline, post-operatively 3 months and 6 months

Secondary Outcome Measures

Name	Time	Method
Clinical attachment level gain	baseline, post-operatively 3 months and 6 months

Trial Locations

Locations (1)

Datta Meghe Institute of Medical sciences Sharad Pawar Dental College; 🇮🇳 Wardha, MAHARASHTRA, India

Datta Meghe Institute of Medical sciences Sharad Pawar Dental College

🇮🇳Wardha, MAHARASHTRA, India

Dr Ruchika Lulla

Principal investigator

7588752199

ruchika.lulla@gmail.com